Table I.
Patient characteristics.
| Case no. | Gender | Age, years | Diagnosis of PCNSL | Number of MTX cycles | Response | PFS, months | Mortality | Site of enhancement on MRI | Molecular pathologya | Salvage therapy |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 59 | Bx | 15 | CR | 27.7 | No | R thalamus, R temporal lobe | IHC: CD19/CD20+ with κ light chain restriction | HD-MTX, IT cytarabine |
| 2 | M | 77 | Bx | 12 | CR | 6 | Yes | Periventricular WM, crossing CC; R frontal WM; R occipital horn of lateral ventricle | IHC: CD20+; FC: CD20+ with κ light chain restriction | RTX; RTX + TMZ; gamma knife; WBRT |
| 3 | F | 66 | Bx | 4 | CR | 5.4+ | No | L frontoparietal dura | Not performed | None |
| 4 | F | 70 | STR | 8 | PR | 8.5+ | No | L temporal lobe | IHC: CD20+ | IT cytarabine |
| 5 | F | 68 | Bx | 14 | CR | 5.5+ | No | Patchy areas in cortical and subcortical WM and cerebellum | IHC: CD20+ | None |
| 6 | M | 74 | Bx | 12 | PR | 8.4+ | No | Third ventricle, occipital horn of R lateral ventricle, fourth ventricle | FC: CD19/CD20/CD45+ with λ light chain restriction | None |
| 7 | M | 78 | Bx | 3 | PR | 2.9+ | No | R posterior parieto-occipital lobe | FC: CD19/CD20/CD45+ with λ light chain restriction | None |
| 8 | F | 59 | Bx | 11 | PR | 17.9+ | No | CC, septum pellucidum and surrounding WM tracts | FC: CD19/CD20+ with κ light chain restriction | IT cytarabine |
| 9 | F | 19 | CSF | 2 | N/A | N/A | No | CC, L inferior cerebellar hemisphere | FC: decreased CD10/CD20, increased CD28 with κ light chain restriction, normal CD19/45 | N/A |
| 10 | M | 55 | Bx | 9 | CR | 22.1 | No | R frontoparietal lobe | IHC: CD20+ | HD-MTX; ASCT |
| 11 | M | 42 | Bx | 11 | CR | 16.6+ | No | Diffusely in frontal, parietal, temporal and occipital lobes; splenium of CC | IHC: CD20+; FC: CD19/CD20+ | ASCT |
| 12 | M | 50 | Bx | 8 | CR | 13.5+ | Yes | L basal ganglia, L cerebral peduncle | FC: CD19/CD20+ with λ light chain restriction | IT cytarabine; ASCT |
a
On IHC of biopsied tissue or FC analysis of CSF. ASCT, autologous stem cell transplantion; Bx, biopsy; CC, corpus callosum; CD, cluster of differntiation; CR, complete response; CSF, cerebrospinal fluid; FC, flow cytometry; HD-MTX, high-dose methotrexate; IHC, immunohistochemistry; IT, intrathecal; L, left; MRI, magnetic resonance imaging; N/A, not available; PR, partial response; R, right; RTX, rituximab; STR: subtotal resection; TMZ, temozolomide; WM, white matter; WBRT, whole-brain radiotherapy.